Spyre Therapeutics Prices $350 Million Public Offering of Common Stock
Spyre Therapeutics has priced an underwritten public offering of 4,117,648 shares of common stock at $85.00 per share, aiming to raise approximately $350 million. The proceeds will fund the advancement of their programs in Gastroenterology, Rheumatology, and Dermatology, including late-stage development for hidradenitis suppurativa. The offering is expected to close around October 7, 2026, with Jefferies, TD Cowen, Leerink Partners, and Stifel managing the process.
Spyre Therapeutics stock falls on public offering launch
Spyre Therapeutics (NASDAQ:SYRE) shares dropped 2.9% after announcing a public offering of its common stock. The company plans to use the proceeds to advance its clinical programs in Gastroenterology, Rheumatology, and Dermatology, including funding for preclinical studies, clinical trials, manufacturing, and Phase 3 readiness, and to advance SPY072 into late-stage development. The offering is subject to market conditions, and its completion, size, or terms are not assured.
Spyre Therapeutics prices $350M public offering at $85 per share
Spyre Therapeutics announced the pricing of an underwritten public offering of 4.12 million shares of common stock at $85.00 per share, aiming to raise approximately $350 million. The company plans to use the proceeds to advance its clinical pipeline in Gastroenterology, Rheumatology, and Dermatology, including funding preclinical work, clinical trials, and manufacturing. A portion of the funds will also support the late-stage development of SPY072 for hidradenitis suppurativa, with remaining proceeds allocated to research and development and general corporate purposes.
Spyre Therapeutics prices $350M stock offering at $85/share
Spyre Therapeutics Inc. has priced an underwritten public offering of 4,117,648 shares of common stock at $85.00 per share, expecting to raise approximately $350.0 million in gross proceeds. The company plans to use these proceeds to advance its programs in Gastroenterology, Rheumatology, and Dermatology, including funding preclinical studies, clinical trials, and manufacturing. This also includes moving SPY072 into late-stage development for hidradenitis suppurativa, with remaining funds allocated to general research, development, and corporate purposes.
Spyre Therapeutics launches public stock offering
Spyre Therapeutics Inc. has announced the commencement of an underwritten public offering of its common stock, with plans to grant underwriters an option to purchase additional shares. The biotechnology company intends to use the net proceeds to advance its gastroenterology, rheumatology, and dermatology programs, including funding for preclinical studies, clinical trials, and late-stage development of SPY072. The offering is contingent on market conditions, and its completion, size, and terms are not guaranteed.
Spyre Therapeutics launches underwritten public offering of common stock
Spyre Therapeutics has initiated an underwritten public offering of its common stock to finance its immunology pipeline, focusing significantly on advancing SPY072 into late-stage development for hidradenitis suppurativa. The net proceeds are intended for preclinical studies, clinical trials, and manufacturing, with Jefferies, TD Cowen, Leerink Partners, and Stifel acting as joint book-running managers. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares, providing flexibility for further capital if demand is high.
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Spyre Therapeutics has announced a proposed underwritten public offering of common stock to secure funding for its ongoing development programs. The proceeds will primarily support advancing its Gastroenterology, Rheumatology, and Dermatology programs through clinical stages, including Phase 3 readiness, and initiating late-stage development for SPY072 in hidradenitis suppurativa. The offering's completion is contingent on market and other conditions.
Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $115
Wells Fargo has reiterated its Buy rating for Spyre Therapeutics (SYRE.US), maintaining its price target at $115. This suggests continued confidence from Wells Fargo in the company's financial prospects and stock performance.
Spyre Therapeutics’ chief legal officer sells $2.63m in shares
Spyre Therapeutics' chief legal officer, Heidy King-Jones, sold shares worth over $2.63 million on October 1, 2026, after exercising stock options. These transactions were executed under a Rule 10b5-1 trading plan. Despite the stock's significant surge over the past year, InvestingPro analysis suggests it may be overvalued.
CEO Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE)
Cameron Turtle, CEO of Spyre Therapeutics Inc (SYRE), sold 15,000 shares of the company on October 1, 2026, at $92.01 per share. This transaction is part of a larger trend of insider selling at SYRE, with 30 insider sells and 0 buys over the past year. Investors are advised to consider this insider activity alongside the company's clinical pipeline progress and financial position.
Spyre Therapeutics CEO Cameron Turtle sells $1.38m in SYRE stock
Spyre Therapeutics CEO Cameron Turtle sold 14,000 shares of SYRE stock for approximately $1.38 million on October 1, 2026, under a Rule 10b5-1 trading plan. This sale follows a significant 487% surge in the stock over the past year, though InvestingPro analysis suggests it's currently overvalued. The company faces profitability challenges despite recent mixed clinical trial results and varying analyst ratings.
CEO Cameron Turtle sells 15,000 shares of Spyre Therapeutics (SYRE) under a trading plan.
Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock on October 1, 2026, through six transactions under a Rule 10b5-1 trading plan. The shares were sold at weighted average prices ranging from $89.14 to $93.37, and one transaction at $93.91. Following these sales, Turtle's direct holdings in common stock are 537,540 shares.
After exercising $14.50 options, Spyre Therapeutics (SYRE) legal chief sells 28,933 shares.
Heidy King-Jones, Chief Legal Officer and Corporate Secretary of Spyre Therapeutics (SYRE), exercised options for 28,933 common shares at $14.50 per share on October 1, 2026. She subsequently sold these shares in five separate transactions under a Rule 10b5-1 trading plan, with weighted-average sale prices ranging from $89.24 to $93.46 per share. Following these transactions, her reported post-exercise stock-option position was 482,478 underlying shares.
Spyre Therapeutics Officer Heidy King-Jones Files Form 144 to Sell 29,335 Shares Under 10b5-1 Plan
Heidy King-Jones, an officer at Spyre Therapeutics (NASDAQ:SYRE), has filed a Form 144 to sell 29,335 shares of common stock, valued at over $2.6 million, under a pre-established Rule 10b5-1 trading plan. These shares will be acquired through stock option exercises. King-Jones has also made previous sales under the same plan in September 2026.
J.P. Morgan Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $110
J.P. Morgan has initiated coverage on Spyre Therapeutics (SYRE.US) with a "Buy" rating. The investment bank has set a target price of $110 for the company's stock. This new rating and price target indicate a positive outlook from J.P. Morgan regarding Spyre Therapeutics' future performance.
45,000 shares are proposed for sale at Spyre Therapeutics (SYRE), following two earlier sales.
Cameron Turtle has filed a Form 144 notice to sell 45,000 common shares of Spyre Therapeutics (SYRE) with an aggregate market value of $4.01 million. These shares were obtained from previously exercised stock options dated June 15, 2023, and the approximate sale date is October 1, 2026. The filing also reports two prior 10b5-1 sales: 15,000 shares on August 3, 2026, for $1.43 million, and another 15,000 shares on September 1, 2026, for $1.31 million.
After a $2.44M September sale, an officer proposes selling more Spyre Therapeutics (SYRE) shares.
Heidy King-Jones, an officer at Spyre Therapeutics (SYRE), plans to sell 29,335 common shares worth approximately $2.61 million on October 1, 2026. This proposed sale follows two previous 10b5-1 sales by King-Jones in September 2026, totaling over $2.4 million. The shares were and will be acquired through stock-option exercises.
Spyre stock draws new Overweight at J.P. Morgan (SYRE:NASDAQ)
J.P. Morgan initiated coverage on Spyre Therapeutics (SYRE) with an Overweight rating and a $110 price target for year-end 2027. Analyst Hardik Parikh highlighted the company's strong potential in treating inflammatory bowel disease (IBD) as the primary driver for the positive outlook. This news led to a rise in Spyre Therapeutics' stock price on Thursday.
JPMorgan initiates Spyre stock with Overweight on IBD pipeline By Investing.com
JPMorgan has initiated coverage on Spyre Therapeutics Inc. (NASDAQ:SYRE) with an Overweight rating and a $110 price target, citing the company's strong inflammatory bowel disease (IBD) pipeline. Spyre's stock has seen a significant 441% gain over the past year, with JPMorgan projecting substantial upside potential, particularly from its combination therapies set to deliver Phase 2 readouts in 2027. The firm believes Spyre could capture a low-teens percentage share of the U.S. advanced biologics IBD market by the 2040s, leading to annual worldwide sales of $6 billion to $7 billion.
SYRE Stock Steadies As SPY003 Trial Data De-Risks IBD Pipeline
Spyre Therapeutics (SYRE) stock is trending up after positive Phase 2 SKYLINE trial data for SPY003 in ulcerative colitis, hitting its primary endpoint and de-risking its IBD pipeline. This win, combined with validated SPY001 and SPY002, establishes a multi-mechanism IBD platform. Despite strong data, the stock's premarket reaction was modest, and insider selling around September 1, 2026, suggests high expectations were already priced in, making SYRE a volatile but catalyst-driven stock.
SYRE Stock Steadies As SPY003 Data Resets Biotech Expectations
Spyre Therapeutics (SYRE) stock is up 5.22% after positive Phase 2 SKYLINE data for its SPY003 drug, which met its primary endpoint for ulcerative colitis. Despite the strong clinical results, shares traded modestly lower initially, suggesting high market expectations and a "wait and see" approach from traders for combination therapy and later-stage data. The company has a strong balance sheet with over $1.1B in cash, enabling continued pipeline development, and has upcoming Phase 2 readouts for SPY072 in late 2026.
Spyre Therapeutics gains as investors continue to digest positive Phase 2 bowel disease data
Spyre Therapeutics (SYRE) saw a 5.1% increase in its stock price, likely due to sustained investor confidence following positive Phase 2 clinical trial results for its ulcerative colitis treatment, SPY003. The company announced strong 12-week topline results in early September, meeting its primary endpoint and demonstrating clinical remission and endoscopic improvement. Despite significant insider selling over the past six months, institutional investors have shown mixed activity, with some adding substantial shares while others reduced their positions.
Spyre Therapeutics (SYRE) Stock Price, News & Analysis
Spyre Therapeutics (SYRE) is a clinical-stage biotechnology company developing long-acting antibodies for inflammatory bowel disease (IBD) and rheumatic diseases. The company's pipeline includes investigational antibodies SPY001, SPY002, SPY072, and SPY003, designed for infrequent subcutaneous dosing, and it is exploring rational combinations of these therapies. Recent news highlights include positive Part A induction results for SPY003 and progress in its SKYLINE and SKYWAY Phase 2 clinical trials.
Spyre Therapeuticsの社内関係者が保有株を28%削減
この記事は日本語であり、Spyre Therapeuticsの社内関係者が保有株を28%削減したという情報のみを提供しています。詳細な内容や文脈は記事の本文に含まれていません。
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $121
JonesTrading has reaffirmed its Buy rating for Spyre Therapeutics (SYRE.US) and maintained its target price at $121. This indicates continued confidence from the firm in the company's prospects and valuation.
Spyre Therapeutics, Inc. (SYRE) stock price, news, quote and history
This article provides a detailed financial overview of Spyre Therapeutics, Inc. (SYRE), including its current stock price, historical data, key financial metrics, and analyst insights. It highlights the company's focus on developing therapeutics for inflammatory bowel disease and rheumatic diseases, outlining its primary drug candidates and their development stages. The report also covers Spyre Therapeutics' significant year-to-date and 1-year stock performance.
Total liabilities of Spyre Therapeutics, Inc – MUN:3920
This page provides financial information for Spyre Therapeutics, Inc (MUN:3920) on TradingView, specifically focusing on its total liabilities. It outlines where the data is sourced from, including ICE Data Services and FactSet, and notes the market status as closed with no trades.
Price to earnings ratio of Spyre Therapeutics, Inc – MUN:3920
This page from TradingView displays the "Price to earnings ratio" for Spyre Therapeutics, Inc. It appears to be a financial data placeholder, indicating no current trades or specific values for the ratio are available. The content primarily consists of navigation links and copyright information rather than substantive financial analysis.
Equity in earnings of Spyre Therapeutics, Inc – MUN:3920
This article displays the financial overview for Spyre Therapeutics, Inc (MUN:3920) on TradingView, specifically focusing on its "Equity in earnings" metric. It indicates that the market for this stock was closed with no trades recorded at the time of viewing. The page provides a general financial overview and links to various TradingView features and market data sources.
Spyre Therapeutics, Inc Income Statement – MUN:3920
This article provides an income statement overview for Spyre Therapeutics, Inc. (MUN:3920), detailing key financial metrics from 2014 to 2025. It presents annual and quarterly earnings reports to help users understand the company's performance, including revenue, expenses, and profit figures, although most detailed financial data for the listed years is currently unavailable.
Price to cash flow ratio of Spyre Therapeutics, Inc – MUN:3920
This article provides financial information for Spyre Therapeutics, Inc. (MUN:3920) on TradingView, specifically focusing on its price-to-cash flow ratio. It indicates that the market is currently closed with no trades. The content primarily consists of navigation and platform features with limited actual financial data presented directly.
Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests
Spyre Therapeutics (SYRE) announced that all three of its anti-IL-23 antibodies (SPY001, SPY002, SPY003) achieved primary endpoints in the monotherapy Part A of their Phase 2 SKYLINE trial for inflammatory bowel disease (IBD). This success establishes proof-of-concept for each molecule individually, paving the way for combination therapy tests in Part B, with results expected in 2027. Despite positive trial news and substantial cash reserves, the company continues to burn cash, and its combination strategy remains unproven, leading to a split between bullish investors and skeptics.
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
Spyre Therapeutics has successfully completed its three-pronged approach to inflammatory bowel disease (IBD) with its anti-IL-23 antibody, SPY003, demonstrating a win in a phase 2 ulcerative colitis (UC) study. This success follows positive readouts for its other investigational antibodies, SPY001 and SPY002, earlier in the year. The company believes these combinations have the potential to significantly improve upon current standard-of-care treatments for IBD.
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
Spyre Therapeutics has announced positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY003, an anti-IL-23 treatment for ulcerative colitis. The trial met its primary endpoint with a statistically significant reduction in the Robart's Histopathology Index score, demonstrating SPY003's potential as a best-in-class therapy. These results complete the proof-of-concept for all three components of Spyre's IBD combination therapies, with Part B of the SKYLINE trial currently enrolling patients for combination evaluations.
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares
Heidy King-Jones, an officer at Spyre Therapeutics (NASDAQ:SYRE), sold approximately $2.48 million worth of shares and acquired $411,785 worth of shares on September 1 and 2, 2026, through a pre-arranged trading plan. The sales occurred after Spyre's stock surged over 413% in the past year, leading to an InvestingPro analysis suggesting the stock is overvalued. King-Jones's transactions involved both sales at high prices and the exercise of stock options at a lower exercise price, increasing her direct beneficial ownership to 2,845 shares.
Spyre Therapeutics Insider Sold Shares Worth $2,283,821, According to a Recent SEC Filing
Scott L Burrows, the Chief Financial Officer of Spyre Therapeutics, sold 25,732 shares in the company on September 01, 2026. This transaction was valued at $2,283,821, according to a recent SEC filing. The article highlights this insider trading activity at Spyre Therapeutics.
Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing
Cameron Turtle, the Director and Chief Executive Officer of Spyre Therapeutics, sold 15,000 shares of the company's stock on September 01, 2026, totaling $1,309,410. This transaction was disclosed in a recent SEC filing. Access to the full details of this report requires a premium subscription.
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares
Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of the company's common stock for a total of $1,309,410 on September 1, 2026, pursuant to a Rule 10b5-1 trading plan. Following the sale, Mr. Turtle directly holds 552,540 shares. The sale comes after a significant 414% return over the past year, and amid mixed analyst opinions following recent clinical trial results for SPY072/TL1A and SPY001/SPY002.
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
Spyre Therapeutics, Inc. announced its management will participate in three investor conferences in September 2026: the Citi 2026 BioPharma Back to School Conference, the Wells Fargo 21st Annual Healthcare Conference, and the Stifel 2026 Virtual Immunology and Inflammation Forum. The clinical-stage biotechnology company focuses on developing next-generation therapies for immunology. Management will also hold one-on-one investor meetings, with webcasts of the events available on their investor relations website.
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
Shares of Spyre Therapeutics (SYRE) have dropped 16.6% since its last earnings report, underperforming the S&P 500. The company reported a narrower-than-expected Q2 2026 loss of 36 cents per share, with operating expenses aided by gains from the sale of an in-process research and development asset. Analysts have shown a downward trend in earnings estimate revisions for SYRE, which currently holds a Zacks Rank #3 (Hold) and an overall VGM Score of F.
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced its participation in three upcoming investor conferences in September 2026: the Citi 2026 BioPharma Back to School Conference, the Wells Fargo 21st Annual Healthcare Conference, and the Stifel 2026 Virtual Immunology and Inflammation Forum. Management will present and host one-on-one meetings at these events, with webcasts available on the company's investor relations website. The company aims to develop next-generation therapies for immunology.
Multimillion-dollar stock sale planned by Spyre Therapeutics (SYRE) officer—see how many shares are on the block
Heidy King-Jones, an officer at Spyre Therapeutics (SYRE), plans to sell up to 46,665 shares of common stock, valued at approximately $4.17 million, starting around September 1, 2026. The shares will be acquired through the exercise of stock options over the next three months and sold via Morgan Stanley Smith Barney LLC Executive Financial Services. This transaction is disclosed through a Rule 144 notice, indicating an aggregate market value for the shares and noting 88,173,762 shares outstanding as of the planned sale start date.
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles
Spyre Therapeutics announced that its rheumatoid arthritis program failed to meet internal benchmarks, causing its stock to tumble. The company did not provide further details on the specific benchmarks missed or the future of the program.
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
Spyre Therapeutics' antibody drug, SPY072, did not meet internal expectations in a mid-stage trial for rheumatoid arthritis, causing the company's shares to fall by 13% and erasing over $1 billion in market value. While the drug showed some activity and proof-of-mechanism, it was not deemed sufficient for further monotherapy development in RA. Spyre will now focus on advancing SPY072 for other autoimmune conditions like psoriatic arthritis and axial spondyloarthritis.
SYRE Maintained by Wedbush -- Price Target Lowered to $123.00
Wedbush maintained an "Outperform" rating for Spyre Therapeutics Inc (SYRE) but lowered its price target from $130.00 to $123.00, reflecting a cautious outlook. The company has a low GF Score™ of 26/100, indicating weaknesses in profitability and growth, and has seen significant insider selling despite its strong financial strength. Investors are advised to be cautious due to the high valuation and insider activity.
Deutsche Bank Adjusts Spyre Therapeutics PT to $127 From $135, Maintains Buy Rating
Deutsche Bank has adjusted its price target for Spyre Therapeutics (SYRE) to $127, down from $135, while reiterating a Buy rating on the stock. This update reflects a revised valuation by the bank. Meanwhile, Wedbush also adjusted its price target for Spyre Therapeutics to $123 from $130, maintaining an Outperform rating.
S&P 500 Futures Flat in Premarket Trading; Spyre Therapeutics, Intuit Lag
S&P 500 futures were trading flat in premarket activity. Meanwhile, Spyre Therapeutics and Intuit were lagging, while Summit Therapeutics Inc. (SMMT) and J.M. Smucker Co. (SJM) showed gains. Summit Therapeutics was up 8.3% and J.M. Smucker Co. was up 5.2% in pre-market trading.
Spyre Therapeutics (NASDAQ:SYRE): Why Is It in Focus After It reported topline results from a rheumatoid-arthritis substudy?
Spyre Therapeutics (NASDAQ:SYRE) is in focus after announcing topline results from a rheumatoid-arthritis substudy. This development places immune-mediated disease, clinical evidence, and pipeline sequencing at the forefront of the company's narrative, requiring diligent execution and customer response for long-term relevance. The article emphasizes that the news provides a current reference point for the market to assess how the business manages immune-mediated disease while balancing clinical evidence and pipeline sequencing.
Stifel reiterates Spyre stock Buy rating after RA study results
Stifel maintained a Buy rating and $123.00 price target for Spyre Therapeutics (NASDAQ: SYRE) despite mixed results from a rheumatoid arthritis sub-study that did not support monotherapy development. The firm highlighted that the majority of Spyre's current valuation hinges on upcoming Phase 2 data for ulcerative colitis combination therapy, expected next year. The stock has seen significant growth, up over 529% in the past year, though InvestingPro analysis suggests it may be overvalued.
Spyre Therapeutics reports statistically significant Phase 2 RA signals for SPY072 but will not prioritize monotherapy
Spyre Therapeutics announced Phase 2 SKYWAY-RA trial results for SPY072, showing statistically significant benefits over placebo in rheumatoid arthritis (RA) key endpoints. Despite these positive signals, the company will not prioritize SPY072 for monotherapy development in RA, choosing instead to focus on broader TL1A potential and combination strategies. Future readouts for SPY072 in PsA/axSpA are expected in Q4 2026, and for SPY072 combined with IL-17A/F in HS in late 2027/early 2028.
